The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli ...
Demand for Zepbound and Mounjaro has been so hot that Eli Lilly has struggled to make enough, leading the FDA to place it on ...
Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...
The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication ...
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...
The FDA declared a shortage of popular weight-loss and diabetes drugs. Here's what that means for people who get generic ...